Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir [PSI-5004] for 3TC [lamivudine] in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART [highly active antiretroviral therapy Regimen Containing Lamivudine

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir [PSI-5004] for 3TC [lamivudine] in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART [highly active antiretroviral therapy Regimen Containing Lamivudine

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2008

At a glance

  • Drugs Lamivudine; PSI 5004
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top